新闻中心-恒赛生物

Hengsai Bio 2024 Annual Meeting & Spring Tour Special
April 19, 2024 393
Preface: The dragon is in full bloom, welcome the spring, the elite gathered, the annual event. Looking back to 2023, it is to overcome difficulties and move forward; looking forward to 2024, it is to compete with a hundred boats and oar first. Accompanied by the spring breeze in April, Hengsai Bio held the 2024 annual meeting and spring recreation activities in Anji, Zhejiang Province Spring Sequence Annual feast On April 12, all the staff in a relaxed and happy atmosphere...
View details
China's First! Hengsai Bio's Original DC Vaccine KSD-101 Receives FDA IND Approval
March 31, 2024 414
China's First! Hengsai Bio's Original DC Vaccine KSD-101 Receives FDA IND Approval
View details
Hengsai Biologicals Completes Tens of Millions of Dollars in Series A+ Financing
January 17, 2024 258
Hengsai Biologicals Completes Tens of Millions of Dollars in Series A+ Financing
View details
2023 ASH | Hengsai Biotechnology to go to the international academic stage and present the latest research results of hematological oncology
December 15, 2023 278
Hengsai Bio USA - San Diego The 65th Annual Meeting of the American Society of Hematology (ASH) was grandly held in San Diego, USA on December 9-12, 2023. As the largest, most numerous and most influential annual meeting in the field of international hematology, this year's ASH Congress gathered 35,000 specialists and scholars from 109 countries and regions around the world to present their latest achievements, exchange ...
View details
Hengsai Biologicals Completes $100 Million Series A Financing
November 27, 2023 405
Hengsai Biologicals Completes $100 Million Series A Financing, with MaiPai Capital as Exclusive Financial Advisor
View details

News Center

Hengsai Bio 2024 Annual Meeting & Spring Tour Special

China's First! Hengsai Bio's Original DC Vaccine KSD-101 Receives FDA IND Approval

Hengsai Biologicals Completes Tens of Millions of Dollars in Series A+ Financing

2023 ASH | Hengsai Biotechnology to go to the international academic stage and present the latest research results of hematological oncology

Hengsai Biologicals Completes $100 Million Series A Financing

Follow the public number